Yee Lu Tham , M.D. - Publications

Publications, Abstracts

Selected publications:

Tham YL, Verani M, Chang J. Reversible and Irreversible Cardiac Dysfunction Associated with Trastuzumab in Breast Cancer. Breast Cancer Res Treat. 2002 74(2):131-4. [PDF]

Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H, O'Connell P. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol. 2005 23(6):1169-77. [PDF]

Tham YL, Gomez F, Mohsin S, Gutierrez MC, Weiss H, Hilsenbeck S, Elledge R, Chamness G, Osborne CK, Allred DC, Chang JC. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat. 2005 94(3):279-84. [PDF]

Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause. J Support Oncol. 2006 4(6):295-98. [Abstract]

Tham YL, Hinckley L, Elledge R. Long term clinical response in leptomeningeal metastasis from breast cancer treated with monotherapy capecitabine – a case report. Clin Breast Cancer. 2006 7(2):164-6 [PDF]

Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system (CNS) metastases. Cancer. 2006; 107(4): 696-704 [PDF]

Tham YL, Elledge R. Author Reply to Correspondence re: Primary breast cancer phenotypes associated with propensity for central nervous system (CNS) metastases. Cancer. 2006 107(10):2521-2. [PDF]

Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Clinical and biological factors associated with central nervous system metastases in breast cancer. The Amer J of Hematology/Oncology. 2007 6(2):106-108.

Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. Chemotherapy-induced amenorrhea is increased in patients treated with adjuvant doxorubicin and cyclophosphamide (AC) followed by a taxane. AmJ Clin Oncol. 2007 30(2):126-32. [PDF]
Publications, Abstracts

Abstracts:

Tham YL, Lu HH, Teh BS, MacGregor D, Shabab I, Diaz-Marchan P, Lynch GR. Intracranial Hodgkin’s Lymphoma in Both HIV Negative and Positive Patients. 2001 Pan Pacific Lymphoma Conference, 2001.

Lu HH, Tham YL, Shabab I, Teh BS. Nasal T-cell Lymphoma in a Pregnant Patient: A Case Presentation. 2001 Pan Pacific Lymphoma Conference, 2001.

Tham YL, Yogerswaren S, Lu HH, Edwards C, Chiu JK, Lynch GR, Teh BS. Chemo-radiation for bulky cervical carcinoma during second trimester pregnancy, Proc Am Soc Clin Oncol 2003 22 abstract 1967

Kramer R, Tham Y, Sexton K, Friedman L, Weiss H. Chemotherapy-induced amenorrhea is increased in patients treated with adjuvant doxorubicin and cyclophosphamide (AC) followed by a taxane (T). Proc Am Soc Clin Oncol 2005 June 23(16S) abstract 651 (poster presentation)

Tham YL, Gutierrez C, Weiss H, Mohsin S, Hilsenbeck S, Elledge R, Chamness G, Osborne CK, Allred DC, Chang JC. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancer. Proc Am Soc Clin Oncol 2005 June 23(16S) abstract 780

Tham YL, Sexton K, Weiss H, Freidman LC, Kramer R. Chemotherapy containing taxanes (Taxol or Taxotere) increased the risk of cessation of menses in premenopausal women. Mission Conference of the Susan G Komen Breast Cancer Foundation, June 5-7, 2005. (poster presentation)

Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Breast cancer phenotype associated with a propensity for central nervous system (CNS) metastases. 3rd Annual Cancer Center Symposium, Baylor College of Medicine, Nov 1, 2005. (oral presentation)

Tham YL, Sexton K, Kramer R, Weiss H, Grollman J, Minnix J, Friedman LC. The adherence of practice guidelines in the assessment of bone health in women with chemotherapy-induced amenorrhea. San Antonio Breast Cancer Symposium Dec 8-11, 2005. (poster presentation)

Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Breast cancer phenotype associated with a propensity for central nervous system (CNS) metastases. San Antonio Breast Cancer Symposium Dec 8-11, 2005. (poster presentation)

Crawford M, Tham YL, Elledge R. Breast cancer in underserved women: Facilitating treatment. Mission Conference of the Susan G Komen Breast Cancer Foundation, June 11-13, 2006. (poster presentation)

Tham YL, Creighton C, Guitierrez C, Osborne CK, Brown P, Chang JC. A gene expression signature of eventual brain metastases in patients with breast cancer. Proc Am Soc Clin Oncol 2007 (poster discussion)

Massarweh SA, Tham YL, Weiss H, Fuqua S, Huang J, Elledge R. A phase II study of anastrozole and fulvestrant in combination with gefitinib in patients with newly diagnosed ER-positive breast cancer. Proc Am Soc Clin Oncol 2007 (poster presentation)
Publications, Abstracts